Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains.
Most human carcinoma cell lines lack the high-affinity receptors for adenovirus serotype 5 (Ad5) at their surface and are nonpermissive to Ad5. We therefore tested the efficiency of retargeting Ad5 to alternative cellular receptors via immunoglobulin (Ig)-binding domains inserted at the extremity of short-shafted, knobless fibers. The two recombinant Ad5's constructed, Ad5/R7-Z(wt)-Z(wt) and Ad5/R7-C2-C2, carried tandem Ig-binding domains from Staphylococcal protein A (abbreviated Z(wt)) and from Streptococcal protein G (C2), respectively. Both viruses bound their specific Ig isotypes with the expected affinity. They transduced human carcinoma cells independently of the CAR pathway, via cell surface receptors targeted by specific monoclonal antibodies, that is, EGF-R on A549, HT29 and SW1116, HER-2/neu on SK-OV-3 and SK-BR-3, CA242 (epitope recognized by the monoclonal antibody C242) antigen on HT29 and SW1116, and PSMA (prostate-specific membrane antigen) expressed on HEK-293 cells, respectively. However, Colo201 and Colo205 cells were neither transduced by targeting CA242 or EGF-R nor were LNCaP cells transduced by targeting PSMA. Our results suggested that one given surface receptor could mediate transduction of certain cells but not others, indicating that factors and steps other than cell surface expression and virus-receptor interaction are additional determinants of Ad5-mediated transduction of tumor cells. Using penton base RGD mutants, we found that one of these limiting steps was virus endocytosis.
Henning
P
P
Got-a-Gene AB, Gothenburg, Sweden.
Andersson
K M E
KM
Frykholm
K
K
Ali
A
A
Magnusson
M K
MK
Nygren
P-A
PA
Granio
O
O
Hong
S S
SS
Boulanger
P
P
Lindholm
L
L
D000260:Adenoviruses, Human / Q000235:genetics*; D000906:Antibodies / Q000378:metabolism*; D015153:Blotting, Western / Q000379:methods; D036022:Capsid Proteins / Q000235:genetics*; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D006801:Humans; D008854:Microscopy, Electron; D009369:Neoplasms / Q000628:therapy*; D011485:Protein Binding; D014161:Transduction, Genetic / Q000379:methods; D014771:Virion / Q000235:genetics; D016662:Virus Integration
D000906:Antibodies; D036022:Capsid Proteins; C018315:hexon capsid protein, Adenovirus